These targeted genes enable LIRA to capture a comprehensive molecular snapshot of the tumor and its microenvironment, encompassing immune activation signals (e.g., CD8+ T cell infiltration, B cell infiltration), immunosuppressive features (e.g., Treg enrichment, histone modification, LRP8‐mediated immunometabolism), and tumor‐intrinsic characteristics. The gene discussed is CD8A; the disease is neoplasm.